Next big Covid-19 treatment may be manufactured antibodies
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Wednesday
August 10, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
WEDNESDAY, AUGUST 10, 2022
Next big Covid-19 treatment may be manufactured antibodies

World+Biz

Reuters
03 August, 2020, 06:35 pm
Last modified: 03 August, 2020, 06:47 pm

Related News

  • Dhaka got $5.83b as Covid recovery support in 3 years
  • Covid-19: 3 deaths, 296 cases reported in 24hrs
  • Agreement signed with World Bank for $300m loan 
  • Children aged 5-11 to get Covid jabs from 11 August
  • BCSIR develops low-priced Covid test kits

Next big Covid-19 treatment may be manufactured antibodies

Reuters
03 August, 2020, 06:35 pm
Last modified: 03 August, 2020, 06:47 pm
Next big Covid-19 treatment may be manufactured antibodies

As the world awaits a Covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders - antibodies designed specifically to attack this new virus.

Development of monoclonal antibodies to target the virus has been endorsed by leading scientists. Anthony Fauci, the top U.S. infectious diseases expert, called them "almost a sure bet" against Covid-19.

When a virus gets past the body's initial defenses, a more specific response kicks in, triggering production of cells that target the invader. These include antibodies that recognize and lock onto a virus, preventing the infection from spreading.

Monoclonal antibodies - grown in bioreactor vats - are copies of these naturally-occurring proteins.

Scientists are still working out the exact role of neutralizing antibodies in recovery from Covid-19, but drugmakers are confident that the right antibodies or a combination can alter the course of the disease that has claimed more than 675,000 lives globally.

"Antibodies can block infectivity. That is a fact," Regeneron Pharmaceuticals executive Christos Kyratsous told Reuters.

Regeneron is testing a two-antibody cocktail, which it believes limits the ability of the virus' to escape better than one, with data on its efficacy expected by late summer or early fall. "Protection will wane over time. Dosing is something we don't know yet," said Kyratsous.

The U.S. government in June awarded Regeneron a $450 million supply contract. The company said it can immediately begin production at its U.S. plant if regulators approve the treatment.

Eli Lilly and Co <LLY.N, AstraZeneca, Amgen, and GlaxoSmithKline were cleared by the U.S. government to pool manufacturing resources in order to scale up supplies if any of these drugs prove successful.

Even with that unusual cooperation among rivals, manufacturing these medicines is complex and capacity is limited. There is also a debate over whether a single antibody will be powerful enough to stop Covid-19.

AstraZeneca said it plans to start human trials of its dual-antibody combination within weeks.

Lilly, which began human testing in June of two antibody candidates in separate trials, is focusing on a one-drug approach.

"If you need a higher dosage or more antibodies, fewer people can be treated," Lilly Chief Scientific Officer Dan Skovronsky said.

'Instant Immunity'

Unlike vaccines, which activate the body's own immune system, the impact of infused antibodies eventually dissipates.

Still, drugmakers say monoclonal antibodies could temporarily prevent infection in at-risk people such as medical workers and the elderly. They could also be used as a therapeutic bridge until vaccines become widely available.

"In a prophylactic setting we think we may achieve coverage for up to six months," said Phil Pang, chief medical officer of Vir Biotechnology, which aims to start testing an antibody in non-hospitalized patients next month with partner GSK.

"The advantage of an antibody is that it is basically instant immunity," said Mark Brunswick, senior vice president at Sorrento Therapeutics, which aims to begin human trials next month of a single antibody candidate.

Safety risks for monoclonal antibodies are considered low, but their cost can be quite high. These type of drugs for cancer can cost over $100,000 a year.

There is also concern that the coronavirus could become resistant to specific antibodies. Researchers are already at work on second-generation compounds with targets other than the crown-like spikes the virus uses to invade cells.

"We are trying to develop something that is complementary," Amgen research chief David Reese said. Amgen is working with Adaptive Biotechnologies Corp.

Researchers in a recent paper published in the journal Nature said they had discovered several new, very potent, antibodies directed to an area where the virus attaches to human cells and to a region of the spike that has not attracted attention.

"To avoid development of resistance you want to target different sites," study author and Columbia University professor David Ho told Reuters.

There are also questions about when in the course of the illness it might be best to employ these new weapons.

"Giving an antibody later on after infection might not be that helpful, said Florian Krammer, microbiology professor at New York's Icahn School of Medicine. "Given early, they probably work well."

COVID-19 / manufactured / antibodies

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BPC says it cannot bear losses anymore
    BPC says it cannot bear losses anymore
  • Cargo ships pass a sandbank near Bendorf on the Rhine. Photographer: Thomas Frey/picture alliance/Getty Images
    Historic drought threatens to cripple european trade
  • File Photo/ UNB
    Inflation to shoot up with oil price hike: Finance minister

MOST VIEWED

  • Russian President Vladimir Putin attends a meeting with Chinese President Xi Jinping in Beijing, China February 4, 2022. Sputnik/Aleksey Druzhinin/Kremlin via REUTERS
    China calls US 'main instigator' of Ukraine crisis
  • Zhou Xiaoxuan, also known by her online name Xianzi, weeps as she arrives at a court for a sexual harassment case involving a Chinese state TV host, in Beijing, China December 2, 2020. REUTERS/Florence Lo/File Photo
    Chinese court rejects TV intern's #MeToo case appeal
  • 
The Sri Lanka Navy patrol team inspects a fishing boat during a random search operation, amid the country&#039;s economic crisis, in Colombo, Sri Lanka, July 29, 2022. REUTERS/Dinuka Liyanawatte
    The high price of a Sri Lankan family's bid to flee crisis
  • Former Pakistan PM Khan's aide, TV channel face sedition charges
    Former Pakistan PM Khan's aide, TV channel face sedition charges
  • Money Saving Expert founder Martin Lewis said the Government must intervene now to avoid a crisis in the energy market (Photo: Kirsty O’Connor/PA Wire)
    Martin Lewis warns of energy crisis ‘on scale of pandemic’
  • Cargo ships pass a sandbank near Bendorf on the Rhine. Photographer: Thomas Frey/picture alliance/Getty Images
    Historic drought threatens to cripple european trade

Related News

  • Dhaka got $5.83b as Covid recovery support in 3 years
  • Covid-19: 3 deaths, 296 cases reported in 24hrs
  • Agreement signed with World Bank for $300m loan 
  • Children aged 5-11 to get Covid jabs from 11 August
  • BCSIR develops low-priced Covid test kits

Features

The elevated ground is made out of soil on which grass and trees have grown. This grass-covered elevated ground extends to the perimeter of the establishment. Photo: Maruf Raihan

Aman Mosque: Where form and function complement each other

1d | Habitat
Photo: BSS

Begum Fazilatunnessa Mujib . . . woman of moral power

2d | Thoughts
Will Glass Cosmetics be your next skincare holy grail?

Will Glass Cosmetics be your next skincare holy grail?

2d | Brands
Akij Tableware: More than just dishes on a table

Akij Tableware: More than just dishes on a table

2d | Brands

More Videos from TBS

Those who remain in morgue for years after death

Those who remain in morgue for years after death

1h | Videos
Is Donald Trump getting caught in tax evasion case?

Is Donald Trump getting caught in tax evasion case?

1h | Videos
Western Europeans adopt various strategies to avoid heat

Western Europeans adopt various strategies to avoid heat

1h | Videos
Why are we forgetting 'everything'?

Why are we forgetting 'everything'?

3h | Videos

Most Read

1
Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 
Banking

Dollar crisis: BB orders removal of 6 banks’ treasury chiefs 

2
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

3
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

4
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

5
Photo: Collected
Transport

Will Tokyo’s traffic model solve Dhaka’s gridlocks?

6
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]